Drug Profile


Alternative Names: NCO 650

Latest Information Update: 02 Nov 2007

Price : $50

At a glance

  • Originator Nippon Chemiphar
  • Class Antiallergics; Antiasthmatics; Small molecules
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Asthma

Most Recent Events

  • 12 Aug 1997 No-Development-Reported for Asthma in Japan (Unknown route)
  • 26 Aug 1994 Discontinued-I for Asthma in Sweden (Unknown route)
  • 26 Aug 1994 Phase-II clinical trials for Asthma in Japan (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top